Agios Pharmaceuticals, Inc. (AGIO)

Market Cap	2.10B
Revenue (ttm)	37.04M
Net Income (ttm)	665.99M
Shares Out	57.92M
EPS (ttm)	11.45
PE Ratio	3.17
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	704,531
Open	35.20
Previous Close	35.21
Day's Range	35.08 - 36.82
52-Week Range	23.42 - 62.58
Beta	0.73
Analysts	Buy
Price Target	58.60 (+61.52%)
Earnings Date	Jul 31, 2025

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patien...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2013
• Employees: 488
• Stock Exchange: NASDAQ
• Ticker Symbol: AGIO
• Website: https://www.agios.com

Analyst Summary

According to 6 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price target is $58.6, which is an increase of 61.52% from the latest price.

Price Target

$58.6

(61.52% upside)

Analyst Consensus: Buy